HCA
HCA Healthcare, Inc.Evidence as of 2026-09-03Overview · HCA Healthcare, Inc.
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The compa…
Management team
- Ms. Wendy Warren · Senior VP, Chief Ethics & Compliance OfficerFind on LinkedIn
- Dr. Michael S. Cuffe M.B.A., M.D. · Executive VP & Chief Clinical OfficerFind on LinkedIn
- Mr. Michael R. McAlevey · Executive VP and Chief Legal & Administrative OfficerFind on LinkedIn
- Mr. Jon Mack Foster · Executive VP & COOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.0 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Revenue and earnings held steady across the reported quarters: reported revenues were $18,321,000,000 in Q1 2025 (fiscal quarter ended 2025-04-28), $18,605,000,000 in Q2 2025 (fiscal quarter ended 2025-07-31), $19,161,000,000 in Q3 2025 (fiscal quarter ended 2025-10-27) and $19,109,000,000 in Q1 2026 (fiscal quarter ended 2026-04-27). Single-quarter net income stayed around $1.6 billion in each period and diluted EPS rose from $6.45 in Q1 2025 to $7.15 in Q1 2026.
Share-count reduction and buybacks are evident: weighted-average diluted shares outstanding fell from 249,440,000 in Q1 2025 to 226,652,000 in Q1 2026, point-in-time shares fell to 221,839,800 as of 2026-04-27, and repurchase payments of $2,506,000,000 and $1,571,000,000 were reported in Q1 2025 and Q1 2026 respectively. The balance sheet shows rising long-term debt (from $43,031,000,000 as of 2024-12-31 to $44,373,000,000 as of 2026-03-31) and declining cash ($1,933,000,000 as of 2024-12-31 to $940,000,000 as of 2026-03-31), with stockholders’ equity moving progressively more negative to -$6,303,000,000 as of 2026-03-31. The evidence band is Mixed ( +0.0 of a possible +2 ) with high confidence.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenues: fiscal Q1 2025 (2025-01-01 to 2025-03-31) $18,321,000,000; fiscal Q2 2025 (2025-04-01 to 2025-06-30) $18,605,000,000; fiscal Q3 2025 (2025-07-01 to 2025-09-30) $19,161,000,000; fiscal Q1 2026 (2026-01-01 to 2026-03-31) $19,109,000,000.
XBRL companyfacts · 0001193125-26-191444Net income (single quarters) was $1,610,000,000 in fiscal Q1 2025 (2025-01-01 to 2025-03-31), $1,653,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30), $1,643,000,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30) and $1,620,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31).
XBRL companyfacts · 0000950170-25-061895Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 with the 4 filed 28 August 2026 was filed on 2026-08-28.
4 filed 2026-08-28The provided filing record shows the parse_status for this Form 4 as "pending" in the evidence set.
4 filed 2026-08-28Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the past 6 months is -25.9%, which ranks in the 5th percentile of the 547-stock research universe on 2026-09-02.
Moneyta signal set · 2026-09-02weakened in debateMomentum over the past 3 months is +10.9%.
Moneyta signal set · 2026-09-02weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, HCA appears in the IVV ETF with a weight of 0.09% of the fund.
ETF constituents · market dataA Form 4 filing for HCA was recorded with the 4 filed 28 August 2026 and a filed date of 2026-08-28; the parsed record shows parse_status as "pending" and primary_doc_url as null.
Form 4 × 1 (90d window not enforced here)Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A law firm announced an investor investigation regarding HCA Healthcare on 1 September 2026.
News · globenewswire.com · 2026-09-01Coverage highlighted HCA navigating patient volume challenges while reporting growth, presented within a broader investor update context on 1 September 2026.
News · finance.yahoo.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
An insider filing shows Michael R. McAlevey (EVP & Chief Legal & Admin Officer) reported acquisition of 7,769 shares with a reported aggregate value of "$3.3M" on 2026-08-26.
Form 4 · McAlevey Michael R (EVP & Chief Legal & Admin Off.) · $3.3M code J · 2026-08-26The filing lists the transaction action as "code J" in that Form 4/3/5 record dated 2026-08-26.
Form 4 · McAlevey Michael R (EVP & Chief Legal & Admin Off.) · $3.3M code J · 2026-08-26Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model calculates an implied free-cash-flow growth rate of 15.44% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice to trailing-12-month free cash flow (P/FCF) is 25.95 based on FCF TTM of $3,512,000,000 and the given market price.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-specific signals in the provided evidence jointly support a favorable read. Reported revenues and diluted EPS show sequential increases through the sample quarters (fundamentals-0, fundamentals-2), while weighted-average diluted shares outstanding and point-in-time shares declined materially, consistent with meaningful share repurchases (fundamentals-3, fundamentals-4) that mechanically boost per-share metrics. The trailing P/E of 14.68 and P/FCF of ~26 (valuation-1, valuation-2) appear supportive of a valuation read discussed in multiple outlet pieces (news-2), and recent insider acquisition and reported institutional trading activity add corroborating interest (insider-0, news-4). These items together create a cohesive, company-specific bull case that challenges arguments focused only on market-level volatility or headline items.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.37
33 surviving claims rest on 14 distinct sources; the heaviest analyst carries 24% of them, and 96% of what the desk raised survived the debate.
The evidence set is moderately broad (14 distinct sources) but the surviving claims are fairly concentrated: a single analyst/stream accounts for nearly a quarter of the claims and almost the entire desk’s initial findings survived the debate. That combination raises risk that corroboration reflects common-data or common-interpretation effects rather than many independent checks — treat the read as informationally useful but sensitive to new primary filings or large market moves.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 2 in Medical Care Facilities (as of 2026-09-02).
90-day volatility ranks 2nd of 2 in Medical Care Facilities (as of 2026-09-02).
dividend yield ranks 1st of 2 in Medical Care Facilities (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer−0.3 to the score
1 document
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.5 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.5 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 filing
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot+0.3 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on HCA Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.